Europe Radioimmunoassay Market Report

Europe Radioimmunoassay Market Size

The Europe radioimmunoassay market size was valued at USD 104.25 million in 2025 and is anticipated to reach USD 107.72 million in 2026 from USD 139.99 million by 2034, growing at a CAGR of 3.33% during the forecast period from 2026 to 2034

The increasing prevalence of chronic and infectious diseases is primarily driving the radioimmunoassay market in the European region. The assay's accuracy and sensitivity are determined mainly by the quality of the antigens and antibodies used and the separation procedures used. In addition, the in vitro process of the assay is carried out using radioimmunoassay kits. Governments and private organizations across the region are taking initiatives and investing in the healthcare sector to develop infrastructure, research, and development activities. As a result, central laboratory and point-of-care tests encourage market growth. In addition, according to Commonwealth Fund statistics released in January 2019, heart disease is one of the significant causes of mortality in Germany, accounting for about 38 percent of all deaths.

On the other hand, increasing government initiatives help develop tools such as immunoassay analyzers, which are expected to provide lucrative growth opportunities for the market. Furthermore, technological advancements in the healthcare sector, increasing adoption of automated immunoassay analyzers, and growing healthcare spending are surging market growth. In addition, the emergence of the COVID-19 pandemic has led to the radioimmunoassay market. As a result, the consumption of immunoassays has significantly increased during the pandemic period. This has created lucrative opportunities for companies to produce innovative and advanced analyzers. 

However, factors such as the short shelf life of radiolabelled substances, the presence of hazardous, radioactive elements in the assay, and the disposal of radioactive waste are hampering the growth rate of the European radioimmunoassay market.

REGIONAL ANALYSIS

Based on the region, the European region has the second-highest market share globally, only behind the likes of North America, albeit with a low CAGR rate. The low growth rate of the region can be attributed to the fact that most countries in the region are at their pinnacle of development, and the room to grow is fast decreasing. Nevertheless, the European market accounted for a substantial share of the global radioimmunoassay market in 2020, and it is anticipated to continue its dominance throughout the forecast period. The regional market growth is attributed to the presence of a well-established healthcare infrastructure, the presence of key market companies, and favorable reimbursement policies. In addition, emerging countries such as Germany, the UK, France, Italy, and Spain are contributing to the European radioimmunoassay market growth. 

The German radioimmunoassay market accounted for the largest European market share and is likely to witness a significant share during the forecast period. The increasing incidence of cancer, Growing awareness, and Urbanization with a heavy population drive the market growth. Also, the Presence of CROs and pharmaceutical industries, technological advancements in the healthcare sector, and the increasing focus of key market players on developing new products are accelerating the market growth. Germany accounts for a high percentage of diabetes in Europe. According to the International Diabetes Federation, around 15.3 percent of adults in Germany,

Similarly, the UK radioimmunoassay market is expected to register a promising share in the European region in the coming years due to the growing geriatric population and the rising need for quality and error-free results to ensure patient satisfaction and high healthcare spending. 

Furthermore, other emerging countries such as Italy, Spain, and France are expected to witness a considerable share during the forecast period. In addition, a significant increase in research and development activities by the pharmaceutical and biopharmaceutical industries, the rising number of blood donations in blood banks, and continuous technological advancements contribute to the radioimmunoassay market.

KEY MARKET PLAYERS

A few of the prominent companies operating in the Europe radioimmunoassay market include

• DIAsource ImmunoAssays SA
• Beckman Coulter
• IBL International
• PerkinElmer
• DRG International
• MP Biomedicals LLC
• Cisbio
• Euro Diagnostica AB
• DiaS.p.A.
• EMD Millipore
• Izotop
• Berthold Technologies GmbH & Co. KG
• STRATEC Biomedical AG

MARKET SEGMENTATION

This research report on the European radioimmunoassay market has been segmented and sub-segmented into the following categories.

By Type

• Reagents and Kits
• Analyzers

By End User

• Hospitals
• Pharmaceutical Industry and CRO
• Clinical Diagnostic Laboratories

By Application

• Research
• Clinical Diagnostics

By Country

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe